Factor This Power Engineering
Live Events
DTECH® Events
POWERGEN™
INFOCAST Events
Calendar
Webinars
Podcasts
Factor This
This Week in Cleantech
Factor This Policycast
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
POWERGEN™
INFOCAST Events
Podcasts
Factor This
Factor This Policycast
This Week in Cleantech
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Stoke Therapeutics, Inc. - Common Stock
(NQ:
STOK
)
31.10
+1.54 (+5.21%)
Streaming Delayed Price
Updated: 1:05 PM EDT, Aug 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Stoke Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Stoke Therapeutics Q2 Earnings Call Highlights
↗
August 03, 2026
Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR study of zorevunersen in patients with Dravet syndrome remains on track for a data readout in the third quarter of 2027, following completion...
Via
MarketBeat
Topics
Earnings
Stoke Therapeutics Q1 Earnings Call Highlights
↗
May 09, 2026
Stoke Therapeutics (NASDAQ:STOK) said its lead investigational therapy zorevunersen continued to show durable seizure reductions and improvements in measures of cognition and behavior in four-year...
Via
MarketBeat
Topics
Earnings
Stoke Therapeutics (NASDAQ:STOK) Beats Q1 2026 Estimates as Phase 3 Trial Nears Completion
↗
May 07, 2026
Via
Chartmill
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares
↗
March 27, 2026
This biotech innovator in genetic disease therapies reported a notable insider sale amid a year of dramatic share price gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Earnings Scheduled For November 4, 2025
↗
November 04, 2025
Via
Benzinga
Where Stoke Therapeutics Stands With Analysts
↗
August 13, 2025
Via
Benzinga
A Look Ahead: Stoke Therapeutics's Earnings Forecast
↗
August 11, 2025
Via
Benzinga
Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss
March 26, 2026
The biotechnology landscape witnessed a defining moment on March 26, 2026, as Wave Life Sciences (Nasdaq: WVE) released highly anticipated interim Phase 1 data from its INLIGHT trial. The study, which...
Via
MarketMinute
Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally
↗
March 24, 2026
This RNA therapeutics innovator for rare diseases reported a notable insider sale amid a year of dramatic share price gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million
↗
February 22, 2026
Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.
Via
The Motley Fool
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%
↗
February 22, 2026
This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.
Via
The Motley Fool
Topics
Regulatory Compliance
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year
↗
February 22, 2026
This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025
↗
February 22, 2026
Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%
↗
February 22, 2026
Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.
Via
The Motley Fool
Topics
Regulatory Compliance
Top movers in Monday's pre-market session
↗
January 12, 2026
Via
Chartmill
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell?
↗
December 10, 2025
This biotech targeting rare genetic diseases reported a notable insider sale following a year of rapid share price gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Curious about the stocks that are showing activity after the closing bell on Tuesday?
↗
December 09, 2025
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via
Chartmill
6 Analysts Have This To Say About Stoke Therapeutics
↗
November 05, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
November 04, 2025
Via
Benzinga
Examining the Future: Stoke Therapeutics's Earnings Outlook
↗
November 03, 2025
Via
Benzinga
What 4 Analyst Ratings Have To Say About Stoke Therapeutics
↗
October 10, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
July 22, 2025
Via
Benzinga
Earnings Scheduled For August 12, 2025
↗
August 12, 2025
Via
Benzinga
D.R. Horton, IQVIA Holdings, Northrop Grumman And Other Big Stocks Moving Higher On Tuesday
↗
July 22, 2025
Via
Benzinga
This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
↗
July 18, 2025
Via
Benzinga
STOKE THERAPEUTICS INC (NASDAQ:STOK) – A Biotech Stock with Strong Growth Signals
↗
May 29, 2025
STOKE THERAPEUTICS (NASDAQ:STOK) shows strong growth metrics, high profitability improvements, and attractive valuation, making it a candidate for growth investors following Louis Navellier's...
Via
Chartmill
Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar
↗
May 01, 2025
The company beat first-quarter expectations, partly thanks to strong sales of its rare disease drugs.
Via
Investor's Business Daily
Topics
Earnings
Forecasting The Future: 7 Analyst Projections For Stoke Therapeutics
↗
March 18, 2025
Via
Benzinga
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
↗
February 18, 2025
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
February 11, 2025
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
